Senate Republicans released their version of the Trump administration’s “One Big Beautiful Bill Act” on Monday with a few ...

U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s ...

The biopharma industry has hit a setback in its ambition to leverage President Donald Trump’s “big, beautiful bill” to amend ...

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...

A controversial proposal to change the Inflation Reduction Act’s pricing framework for rare disease drugs has been dropped ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

CERo Therapeutics Holdings Inc (NASDAQ:CERO) shares are trading higher Tuesday after the company received U.S. Food and Drug ...

On June 16, 2025, RemeGen Co., Ltd. ('RemeGen', stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand ...

The blood cancer multiple myeloma is deadly. This disease is personal for us because one of our best friends and colleagues died from the complications of this malignancy in 2006.

Investing.com -- CERo Therapeutics Holdings Inc (NASDAQ: CERO) stock surged 191.6% after the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for the company’s lead drug ...

The designation qualifies CERo and CER-1236 for certain incentives, such as FDA assistance in designing clinical trials, access to the FDA Orphan Drug Grants Program, exemption from the drug approval ...